NASDAQ:PSTX Poseida Therapeutics (PSTX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PSTX Stock Alerts $2.19 +0.03 (+1.39%) (As of 02:12 PM ET) Add Compare Share Share Today's Range$2.16▼$2.2750-Day Range$2.00▼$4.1352-Week Range$1.54▼$4.27Volume184,859 shsAverage Volume703,898 shsMarket Capitalization$211.31 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Poseida Therapeutics alerts: Email Address Poseida Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside566.7% Upside$14.67 Price TargetShort InterestBearish6.70% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.06Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.77) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector362nd out of 910 stocksBiological Products, Except Diagnostic Industry49th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingPoseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePoseida Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.70% of the float of Poseida Therapeutics has been sold short.Short Interest Ratio / Days to CoverPoseida Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Poseida Therapeutics has recently increased by 7.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePoseida Therapeutics has received a 73.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Poseida Therapeutics is -0.93. Previous Next 1.7 News and Social Media Coverage News SentimentPoseida Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Poseida Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for PSTX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Poseida Therapeutics is held by insiders.Percentage Held by Institutions46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.77) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Poseida Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Poseida Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPoseida Therapeutics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Poseida Therapeutics Stock (NASDAQ:PSTX)Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More PSTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTX Stock News HeadlinesApril 23, 2024 | americanbankingnews.comPoseida Therapeutics (NASDAQ:PSTX) Receives "Buy" Rating from HC WainwrightApril 18, 2024 | prnewswire.comPoseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 17, 2024 | finance.yahoo.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 17, 2024 | prnewswire.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 16, 2024 | msn.comPalisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare moversApril 9, 2024 | investing.comPoseida reports promising results for myeloma therapyApril 8, 2024 | prnewswire.comPoseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 1, 2024 | prnewswire.comPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerMarch 26, 2024 | msn.comPoseida Therapeutics appoints Syed Rizvi as Chief Medical OfficerMarch 25, 2024 | finance.yahoo.comPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comPoseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 15, 2024 | finance.yahoo.comPSTX Apr 2024 5.000 putMarch 15, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaMarch 13, 2024 | finance.yahoo.comPoseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaMarch 13, 2024 | msn.comPoseida spikes after FDA orphan status for CAR-T therapyMarch 11, 2024 | msn.comEQT, Genie Energy And Other Big Stocks Moving Lower On MondayMarch 10, 2024 | finance.yahoo.comUS$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These ResultsMarch 9, 2024 | finance.yahoo.comPoseida Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 8, 2024 | markets.businessinsider.comBuy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical UpdatesMarch 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)March 8, 2024 | finance.yahoo.comPoseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 8, 2024 | investorplace.comPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | finance.yahoo.comPoseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023March 6, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive PSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PSTX CUSIPN/A CIK1661460 Webwww.poseida.com Phone858-779-3100FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+566.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,430,000.00 Net Margins-190.76% Pretax Margin-190.60% Return on Equity-94.90% Return on Assets-42.16% Debt Debt-to-Equity Ratio0.56 Current Ratio3.18 Quick Ratio3.18 Sales & Book Value Annual Sales$64.70 million Price / Sales3.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book2.04Miscellaneous Outstanding Shares96,490,000Free Float94,463,000Market Cap$212.28 million OptionableOptionable Beta0.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Mark J. Gergen J.D. (Age 61)Executive Chairman of the Board Comp: $920.74kMr. Harry J. Leonhardt Esq. (Age 67)J.D., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $630.23kDr. Kristin Yarema Ph.D. (Age 52)President, CEO & Director Ms. Johanna M. Mylet CPA (Age 36)Chief Financial Officer Mr. Loren WagnerChief Operations OfficerMs. Kristin MartinChief People & Administration OfficerMr. Alexander ChapmanSenior VP of Investor Relations & Corporate CommunicationsDr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell TherapyMs. Lisa PortaleSenior Vice President of Regulatory AffairsDr. Jeffrey W. Winkelman J.D.Ph.D., Senior VP & Chief Patent CounselMore ExecutivesKey CompetitorsCentury TherapeuticsNASDAQ:IPSCKodiak SciencesNASDAQ:KODCardiff OncologyNASDAQ:CRDFGraphite BioNASDAQ:GRPHOptheaNASDAQ:OPTView All CompetitorsInstitutional OwnershipPublic Employees Retirement System of OhioBought 22,700 shares on 2/16/2024Ownership: 0.024%Cantor Fitzgerald L. P.Bought 50,205 shares on 2/15/2024Ownership: 0.053%Tower Research Capital LLC TRC Bought 5,606 shares on 2/13/2024Ownership: 0.011%Dynamic Technology Lab Private LtdBought 10,459 shares on 2/9/2024Ownership: 0.011%Simplex Trading LLCBought 5,200 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions PSTX Stock Analysis - Frequently Asked Questions Should I buy or sell Poseida Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTX shares. View PSTX analyst ratings or view top-rated stocks. What is Poseida Therapeutics' stock price target for 2024? 3 analysts have issued 12-month price targets for Poseida Therapeutics' shares. Their PSTX share price targets range from $10.00 to $20.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 566.7% from the stock's current price. View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts. How have PSTX shares performed in 2024? Poseida Therapeutics' stock was trading at $3.36 at the start of the year. Since then, PSTX shares have decreased by 34.5% and is now trading at $2.20. View the best growth stocks for 2024 here. When is Poseida Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PSTX earnings forecast. How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.09. The business earned $25 million during the quarter, compared to analyst estimates of $12.50 million. Poseida Therapeutics had a negative net margin of 190.76% and a negative trailing twelve-month return on equity of 94.90%. What ETFs hold Poseida Therapeutics' stock? ETFs with the largest weight of Poseida Therapeutics (NASDAQ:PSTX) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA).Global X Genomics & Biotechnology ETF (GNOM). What other stocks do shareholders of Poseida Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM). When did Poseida Therapeutics IPO? Poseida Therapeutics (PSTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO. How do I buy shares of Poseida Therapeutics? Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
